Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

E-52862

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Osteoarthritis is the most common musculoskeletal disease worldwide, often characterized by degradation of the articular… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
Sigma-1 receptor (σ1R) knockout (KO) CD1 mice, generated by homologous recombination, and separate pharmacological studies in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
E‐52862 (S1RA, 4‐[2‐[[5‐methyl‐1‐(2‐naphthalenyl)‐1H‐pyrazol‐3‐yl]oxy]ethyl]‐morpholine), a novel selective sigma 1 receptor (σ1R… Expand
2016
2016
E-52862 is a selective σ1R antagonist currently undergoing phase II clinical trials for neuropathic pain and represents a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Background E-52862 is a Sigma-1 receptor antagonist (S1RA) currently under investigation as a potential analgesic medicine. We… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2014
2014
The therapeutic potential of S1RA (E-52862), a selective sigma-1 receptor (&sgr;1R) antagonist, has been explored in experimental… Expand
2014
2014
We have previously shown that the selective sigma‐1 receptor (σ1R) antagonist S1RA (E‐52862) inhibits neuropathic pain and… Expand
2013
2013
While opioids are potent analgesics widely used in the management of pain, a number of well-known adverse effects limit their use… Expand
Highly Cited
2012
Highly Cited
2012
The synthesis and pharmacological activity of a new series of 1-arylpyrazoles as potent σ(1) receptor (σ(1)R) antagonists are… Expand